K. Robin Yabroff

Nov 7, 2024 | jamanetwork.com | Changchuan Jiang |K. Robin Yabroff |Ryan D. Nipp |Xuesong Han

Introduction Ondansetron, the most commonly recommended antinausea drug for patients with cancer, initially faced high list prices, prompting scrutiny and national campaigns supported by the American Society of Clinical Oncology to reduce use.1,2 However, the introduction of generic ondansetron in 2006 dramatically lowered costs and increased its value, leading to its inclusion on the World Health Organization’s essential medication list for all health systems globally.3 In the US,...

Apr 23, 2024 | acsjournals.onlinelibrary.wiley.com | K. Robin Yabroff |Joanna F. Doran |Jingxuan Zhao |Fumiko Chino

The rising costs of cancer care in the United States are well documented.1-3 Cancer treatments can result in substantial out-of-pocket costs3 and financial toxicity4, 5 for patients and their families.

Dec 14, 2023 | jamanetwork.com | Justin Barnes |K. Robin Yabroff |Fumiko Chino

Unwinding of Medicaid Continuous Enrollment Exposes Millions to Disrupted Care—“Be Kind, Rewind” As part of the COVID-19 pandemic response, states received additional Medicaid funding for maintaining continuous enrollment of beneficiaries. Among patients with cancer, Medicaid provides coverage for approximately 13% of adults younger than 65 years and for older adults via dual Medicare-Medicaid enrollment.

Nov 9, 2023 | jamanetwork.com | Leticia M. Nogueira |Elizabeth Schafer |Kewei Shi |K. Robin Yabroff

Key PointsQuestion  Were there changes in provision of cancer care during the first year of the COVID-19 pandemic in the US? Findings  In this cohort study including 3 504 342 patients diagnosed with cancer, there was a significant decrease in the number of cancer treatments initiated during the first year of the pandemic compared with the expected given previous years’ trends.